AB Science S.A. (ABSCF)

Market Cap	100.21M
Revenue (ttm)	1.11M
Net Income (ttm)	-8.11M
Shares Out	n/a
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	400
Average Volume	8,476
Open	1.260
Previous Close	1.600
Day's Range	1.260 - 1.260
52-Week Range	0.800 - 1.600
Beta	1.59
RSI	30.41
Earnings Date	Sep 30, 2025

About AB Science

AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company’s lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer’s disease, and indolent systemic mastocytosis, as well as in Phase 2 tria...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 39
• Stock Exchange: OTCMKTS
• Ticker Symbol: ABSCF

Financial Performance

In 2024, AB Science's revenue was 1.07 million, an increase of 10.52% compared to the previous year's 970,000. Losses were -7.83 million, -34.66% less than in 2023.

Financial numbers in EUR